Jpmorgan Chase & CO Eagle Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$3.34 - $5.6 $188,088 - $315,358	-56,314 Reduced 96.05%	2,317 $12,000
Q1 2024 May 10, 2024	SELL	$4.26 - $6.51 $12,507 - $19,113	-2,936 Reduced 4.77%	58,631 $307,000
Q4 2023 Feb 12, 2024	SELL	$4.63 - $15.21 $7,301 - $23,986	-1,577 Reduced 2.5%	61,567 $321,000
Q3 2023 Nov 14, 2023	SELL	$15.21 - $22.88 $837,523 - $1.26 Million	-55,064 Reduced 46.58%	63,144 $995,000
Q2 2023 Aug 11, 2023	SELL	$17.74 - $31.87 $210,307 - $377,818	-11,855 Reduced 9.11%	118,208 $2.3 Million
Q1 2023 May 18, 2023	BUY	$25.06 - $34.09 $196,420 - $267,197	7,838 Added 6.41%	130,063 $3.69 Million
Q1 2023 May 11, 2023	BUY	$25.06 - $34.09 $270,898 - $368,512	10,810 Added 9.7%	122,225 $3.47 Million
Q4 2022 Feb 13, 2023	SELL	$24.98 - $39.77 $3.01 Million - $4.79 Million	-120,391 Reduced 51.94%	111,415 $3.26 Million
Q3 2022 Nov 14, 2022	BUY	$26.42 - $47.12 $712,256 - $1.27 Million	26,959 Added 13.16%	231,806 $6.13 Million
Q2 2022 Aug 11, 2022	SELL	$41.26 - $51.35 $1.4 Million - $1.74 Million	-33,892 Reduced 14.2%	204,847 $9.1 Million
Q1 2022 May 11, 2022	SELL	$44.58 - $52.6 $223,212 - $263,368	-5,007 Reduced 2.05%	238,739 $11.8 Million
Q4 2021 Feb 10, 2022	SELL	$45.82 - $56.9 $4.01 Million - $4.98 Million	-87,552 Reduced 26.43%	243,746 $12.4 Million
Q3 2021 Nov 12, 2021	BUY	$43.79 - $55.78 $14.5 Million - $18.5 Million	331,298 New	331,298 $18.5 Million

8.6M

100

Ticker EGRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 13,015,900
Market Cap $7.81M
Description
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.